Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

INTRODUCTION: This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate (MTX) use and disease duration. The ability to predict a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Res Ther
Egile Nagusiak: Weinblatt, Michael E., Fleischmann, Roy, van Vollenhoven, Ronald F., Emery, Paul, Huizinga, Tom WJ, Cutolo, Maurizio, van der Heijde, Désirée, Duncan, Benjamin, Davies, Owen, Luijtens, Kristel, Dougados, Maxime
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644627/
https://ncbi.nlm.nih.gov/pubmed/26568428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0841-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak